I suppose you could invert that (1/C) and say it's in ability to resist charge/discharge (changer energy states) but it doesn't make sense
It supports all Mounjaro and Zepbound doses (2.5mg to 15mg), shows drug concentration curves based on tirzepatide's pharmacokinetics, and uniquely supports microdosing protocols
A recent study demonstrated that NLRP3/caspase-1/GSDMD-mediated pyroptosis in fibroblasts is relatively limited compared with that in macrophages, which express high levels of NLRP3, caspase-1 p20 and GSDMD-NT under LPS plus ATP stress, a strong NLRP3 inflammasome activator and pyroptotic trigger
Patient education minimizes confusion and allows individuals to detect differences early
Researchers study MOTS-C for insulin resistance, obesity, exercise performance, and aging - particularly for its role in metabolic regulation and longevity signaling
I was concerned that starting tirzepatide would make things worse on that front